PENUMBRA INC
NYSE: PEN (Penumbra, Inc.)
Last update: 6 hours ago338.64
-1.98 (-0.58%)
| Previous Close | 340.62 |
| Open | 339.63 |
| Volume | 381,106 |
| Avg. Volume (3M) | 997,600 |
| Market Cap | 13,289,267,200 |
| Price / Earnings (TTM) | 74.75 |
| Price / Earnings (Forward) | 66.67 |
| Price / Sales | 10.18 |
| Price / Book | 9.88 |
| 52 Weeks Range | |
| Earnings Date | 22 Apr 2026 |
| Profit Margin | 3.41% |
| Operating Margin (TTM) | 12.45% |
| Diluted EPS (TTM) | 1.09 |
| Quarterly Revenue Growth (YOY) | 16.30% |
| Quarterly Earnings Growth (YOY) | 256.50% |
| Total Debt/Equity (MRQ) | 18.19% |
| Current Ratio (MRQ) | 6.30 |
| Operating Cash Flow (TTM) | 179.16 M |
| Levered Free Cash Flow (TTM) | 135.83 M |
| Return on Assets (TTM) | 5.82% |
| Return on Equity (TTM) | 3.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Penumbra, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.64% |
| % Held by Institutions | 91.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baillie Gifford & Co | 31 Dec 2025 | 876,325 |
| Rtw Investments, Lp | 31 Dec 2025 | 866,499 |
| Jpmorgan Chase & Co | 31 Dec 2025 | 797,490 |
| Clearbridge Investments, Llc | 31 Dec 2025 | 690,814 |
| Champlain Investment Partners, Llc | 31 Dec 2025 | 601,804 |
| Artisan Partners Limited Partnership | 31 Dec 2025 | 594,112 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 388.00 (Needham, 14.58%) | Buy |
| Median | 374.00 (10.44%) | |
| Low | 349.00 (BTIG, 3.06%) | Hold |
| Average | 371.46 (9.69%) | |
| Total | 4 Buy, 9 Hold | |
| Avg. Price @ Call | 342.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 26 Feb 2026 | 360.00 (6.31%) | Buy | 341.94 |
| Canaccord Genuity | 20 Jan 2026 | 374.00 (10.44%) | Hold | 355.44 |
| 17 Dec 2025 | 359.00 (6.01%) | Buy | 309.26 | |
| RBC Capital | 20 Jan 2026 | 374.00 (10.44%) | Hold | 355.44 |
| BTIG | 16 Jan 2026 | 349.00 (3.06%) | Hold | 350.78 |
| Baird | 16 Jan 2026 | 374.00 (10.44%) | Hold | 350.78 |
| Citigroup | 16 Jan 2026 | 374.00 (10.44%) | Hold | 350.78 |
| 11 Dec 2025 | 350.00 (3.35%) | Buy | 311.40 | |
| Jefferies | 16 Jan 2026 | 374.00 (10.44%) | Hold | 350.78 |
| Leerink Partners | 16 Jan 2026 | 374.00 (10.44%) | Hold | 350.78 |
| Truist Securities | 16 Jan 2026 | 374.00 (10.44%) | Hold | 350.78 |
| 18 Dec 2025 | 370.00 (9.26%) | Buy | 315.35 | |
| Wells Fargo | 15 Jan 2026 | 374.00 (10.44%) | Hold | 350.49 |
| B of A Securities | 05 Jan 2026 | 370.00 (9.26%) | Buy | 315.00 |
| JP Morgan | 18 Dec 2025 | 370.00 (9.26%) | Buy | 315.35 |
| Needham | 17 Dec 2025 | 388.00 (14.58%) | Buy | 309.26 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Boston Scientific announces results for fourth quarter and full year 2025 |
| 15 Jan 2026 | Announcement | Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results |
| 15 Jan 2026 | Announcement | Boston Scientific announces agreement to acquire Penumbra, Inc. |
| 29 Dec 2025 | Announcement | Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |